Palisade Bio Receives Buy Rating from Brookline Capital with $16 Price Target

Palisade Bio (PALI) has received a "Buy" rating from Brookline Capital with a $16.00 price target. The analyst maintains a positive outlook on the stock's performance. Based on one-year price targets from 3 analysts, the average target price is $10.67, implying an upside of 1,309.26% from the current price. The average brokerage recommendation is 1.7, indicating "Outperform" status.

Palisade Bio Inc (PALI) reported a quarterly adjusted loss of 47 cents per share for the quarter ended March 31, 2025. This figure is higher than the same quarter last year, when the company reported EPS of $-4.59. The mean expectation of three analysts for the quarter was for a loss of 70 cents per share, with Wall Street expecting results to range from -84 cents to -48 cents per share [1].

The company reported a quarterly loss of $2.23 million, with no revenue reported, matching analyst expectations. Despite the loss, Palisade Bio shares have risen by 13.0% this quarter and lost 53.4% so far this year.

Brookline Capital has given Palisade Bio a "Buy" rating with a $16.00 price target, maintaining a positive outlook on the stock's performance. The average one-year price target from three analysts is $10.67, implying an upside of 1,309.26% from the current price. The average brokerage recommendation is 1.7, indicating an "Outperform" status [2].

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3RL25R:0-palisade-bio-inc-reports-results-for-the-quarter-ended-march-31-earnings-summary/
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3RL25R:0-palisade-bio-inc-reports-results-for-the-quarter-ended-march-31-earnings-summary/